Sickle cell disease: open trials in Brazil

• NCT05777993

  A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study

  Trial Treatment · Phase 4 · Agios Pharmaceuticals, Inc.

  Hospital de Clínicas da UNICAMP, Campinas · Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul (PUCRS), Porto Alegre · HEMORIO Instituto Nacional de Hematologia, Rio de Janeiro · Praxis Pesquisa Médica, Santo André · Hospital Das Clínicas da Faculdade de Medicina de Ribeirão Preto - USP, São Paulo · Hospital das Clínicas da Faculdade de Medicina da Universidad de São Paulo, São Paulo · GSH Banco de Sangue de São Paulo, São Paulo

  Registry updated 2026-10-28

• NCT06546670

  A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

  Trial Treatment · Phase 1/2 · Novartis Pharmaceuticals

  Ribeirão Preto · São Paulo

  Registry updated 2026-10-27

• NCT06439082

  A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

  Trial Treatment · Phase 3 · Novartis Pharmaceuticals

  Campinas · Ribeirão Preto · Salvador · Sao Jose Rio Preto · São Luís · São Paulo

  Registry updated 2026-10-15

• NCT06975865

  The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

  Trial Treatment · Phase 3 · Sanofi

  Universidade Federal de Goias- Site Number : 0760002, Goiânia · Fundação Bahiana de Infectologia- Site Number : 0760009, Salvador · Hospital Santa Izabel- Site Number : 0760006, Salvador · Fundação Faculdade Regional de Medicina de São José do Rio Preto- Site Number : 0760001, São José do Rio Preto · Hospital Samaritano De Sao Paulo- Site Number : 0760005, São Paulo

  Registry updated 2026-10-15

• NCT06612268

  A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

  Trial Treatment · Phase 3 · Novo Nordisk A/S

  Hemocentro UNICAMP, Distrito de Barão Geraldo - Campinas · MultiHemo - Grupo Oncoclínicas, Recife · Fundação Hemocentro de Ribeirão Preto, Ribeirão Preto · Hemorio-Fundarj, Rio de Janeiro · Hospital Samaritano Higienópolis - Instituto de Conhecimento Ensino e Pesquisa (ICEP), São Paulo · HC da FMUSP Hospital das Clínicas São Paulo, São Paulo

  Registry updated 2026-09-17

• NCT05431088

  A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD

  Trial Treatment · Phase 2/3 · Pfizer

  MultiHemo Servicos Medicos S.A, Recife · Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto - USP, Ribeirão Preto · Instituto Estadual de Hematologia Arthur Siqueira Cavalcanti - HEMORIO, Rio de Janeiro · CPHosp Medicina, Ensino e Pesquisa Ltda, São · Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto, São José do Rio Preto · Esho Empresa de Servicos Hospitalares S A, São Paulo · BP - A Beneficência Portuguesa de São Paulo, São Paulo · Casa de Saude Santa Marcelina, São Paulo · Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo

  Registry updated 2026-08-18

• NCT04657822

  Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

  Trial Treatment · Phase 4 · Novartis Pharmaceuticals

  Ribeirão Preto · Salvador · São Paulo

  Registry updated 2026-06-08

All Sickle cell disease trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error